Unichem Laboratories receives ANDA approval for Apremilast Tablets
Chemical

Unichem Laboratories receives ANDA approval for Apremilast Tablets

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .

  • By ICN Bureau | February 20, 2021

Unichem Laboratories Limited has received ANDA approval for its Apremilast Tablets, 10 mg, 20 mg and 30 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Amgen's Otezla (apremilast) Tablets, 10 mg, 20 mg, and 30 mg.

 

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Register Now to Attend Chem Connect 2025 on August 21th 2025, Novotel Mumbai International Airport

Upcoming Conferences

Chem Connect 2025

August 21, 2025

Other Related stories

Startups

Petrochemical

Energy

Digitization